bupivacaine; meloxicam - Profile

What are the generic drug sources for bupivacaine; meloxicam and what is the scope of freedom to operate?

Bupivacaine; meloxicam is the generic ingredient in one branded drug marketed by Heron Theraps Inc and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupivacaine; meloxicam has eighty-three patent family members in twenty countries.

Summary for bupivacaine; meloxicam

International Patents:	83
US Patents:	16
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bupivacaine; meloxicam

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bupivacaine; meloxicam

Dosage:

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for bupivacaine; meloxicam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No			Y
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No			Y
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No			Y
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No			Y

EU/EMA Drug Approvals for bupivacaine; meloxicam

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Heron Therapeutics, B.V.	Zynrelef	bupivacaine, meloxicam	EMEA/H/C/005205Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).	Withdrawn	no	no	no	2020-09-24

International Patents for bupivacaine; meloxicam

Country	Patent Number	Title	Estimated Expiration
Japan	2019526601	送達系、アミド型局所麻酔薬、およびメロキシカムを含む医薬組成物
European Patent Office	3509601	COMPOSITION PHARMACEUTIQUE COMPRENANT UN SYSTÈME D'ADMINISTRATION, UN ANESTHÉSIQUE LOCAL DE TYPE AMIDE ET UN MÉLOXICAM (A PHARMACEUTICAL COMPOSITION COMPRISING A DELIVERY SYSTEM, AN AMIDE-TYPE LOCAL ANESTHETIC, AND MELOXICAM)
Serbia	61202
China	115025099
Poland	3134070

Investment Scenario, Market Dynamics, and Financial Trajectory for Bupivacaine and Meloxicam

Last updated: February 3, 2026

Summary:
This analysis examines the investment opportunities, market dynamics, and financial forecasts for two widely used pharmaceutical drugs: bupivacaine (a local anesthetic) and meloxicam (a non-steroidal anti-inflammatory drug, NSAID). Both drugs occupy distinct segments within the pain management and anesthesia markets, with unique regulatory, competitive, and commercial considerations shaping their potential growth trajectories.

---

What Is the Market Size and Growth Potential for Bupivacaine and Meloxicam?

Parameter	Bupivacaine	Meloxicam
Global Market Size (2022)	~USD 480 million	~USD 2.7 billion
Compound Annual Growth Rate (CAGR) (2023-2028)	~4-5%	~3-4%
Key Markets	United States, Europe, Asia-Pacific	United States, Europe, Asia-Pacific
Market Drivers	Rising surgical procedures, demand for effective anesthesia	Increasing prevalence of chronic pain, osteoarthritis, aging population
Key Competitors	Lidocaine, ropivacaine	Diclofenac, ibuprofen, other NSAIDs

Sources:

• MarketsandMarkets (2023)
• Grand View Research (2022)

---

What Are Current Market Dynamics Affecting Bupivacaine and Meloxicam?

Bupivacaine

Regulatory Environment:

• Approved by the FDA in the US, EMA in Europe, and other agencies worldwide.
• Regulatory focus on safety enhancements due to cardiotoxicity concerns at high doses.

Manufacturing & Supply Chain:

• Primarily produced by large generic and branded pharmaceutical companies.
• Supply chain disruptions can affect pricing and availability.

Market Competition:

• Dominated by generic manufacturers with low-cost alternatives.
• Limited innovation; focus on extended-release formulations (e.g., liposomal bupivacaine) to improve market share.

Clinical Trends:

• Preference for nerve block or infiltration anesthesia during surgeries.
• Increasing adoption of liposomal formulations (e.g., EXPAREL by Pacira) offers premium pricing.

Meloxicam

Regulatory Environment:

• Well-established safety profile; approved globally, including for osteoarthritis and rheumatoid arthritis.
• The U.S. FDA approved extended-release formulations (e.g., Mobicox).

Market Competition:

• Faces significant competition from other NSAIDs like diclofenac, naproxen, ibuprofen.
• New formulations such as topical and combination therapies being developed.

Clinical & Prescriptive Trends:

• Shift toward targeted, long-acting formulations to improve compliance.
• Growing awareness of gastrointestinal and cardiovascular risks influences prescribing practices.

Pricing & Reimbursement:

• Meloxicam is generally priced higher than over-the-counter NSAIDs, owing to prescription status and formulation.

Regulatory and Policy Impacts

Aspect	Impact on Bupivacaine	Impact on Meloxicam
Post-market surveillance	Increased scrutiny over safety (e.g., cardiotoxicity)	Focus on safety profiles, especially cardiovascular risks
Pricing controls	Potential price pressure from generics	Reimbursement policies influence adoption rates
Innovation incentives	R&D on delivery systems, toxicity reduction	Development of novel formulations, combination drugs

---

Financial Projections and Investment Opportunities

Revenue Projections (2023-2028)

Drug / Formulation	2023 Revenue (USD Million)	2024	2025	2026	2027	2028	CAGR	Comments
Bupivacaine (generic)	480	504	530	557	585	614	4.6%	Growth driven by new formulations, emerging markets
Liposomal Bupivacaine	150	180	210	240	270	300	11.4%	Premium segment with R&D potential
Meloxicam	2,700	2,785	2,870	2,960	3,050	3,140	3.4%	Drivers include aging populations and chronic pain management

Key Investment Opportunities

Area	Description	Potential Returns	Risks
Generic Bupivacaine	High-volume, low-margin segment	Low to moderate, stable revenues	Price erosion, regulatory scrutiny
Liposomal/Extended-release Bupivacaine	Niche, premium segment	High, driven by innovation	Regulatory delays, clinical acceptance
Meloxicam Formulations	Development of topical/long-acting IDs	Moderate to high	Competition, safety concerns
Market Expansion	Emerging markets, hospital settings	High growth potential	Market access hurdles

---

Comparison of Market Strategies for Bupivacaine and Meloxicam

Strategy Aspect	Bupivacaine	Meloxicam
Focus	Extension of delivery duration, safety profile	Improving tolerability, novel formulations
Market Penetration	Target hospitals and anesthesia providers	Rheumatology, primary care
Research & Development	Liposomal technology, reduced cardiotoxicity	Extended-release, topical NSAIDs
Pricing Model	Generic price competition, premium for innovation	Prescription pricing, value-based models

---

Comparison with Alternative Therapies

Drug Class / Alternative	Bupivacaine	Meloxicam
Alternatives	Lidocaine, ropivacaine, regional blocks	Diclofenac, ibuprofen, celecoxib
Advantages	Longer duration, reduced dosing frequency	Better safety profile for chronic use
Disadvantages	Toxicity risk at high doses, limited formulations	Cardiovascular and GI safety concerns

---

FAQs

1. What are the main growth drivers for bupivacaine and meloxicam?

• Bupivacaine's growth is driven by increasing surgical procedures requiring effective anesthesia and innovations like liposomal formulations extending duration.
• Meloxicam's expansion stems from rising prevalence of chronic pain, osteoarthritis, and an aging global population, coupled with the development of long-acting and topical formulations.

2. How do regulatory policies impact the marketability of these drugs?

• Post-market safety concerns can lead to restrictions or increased surveillance, affecting revenue stability.
• The approval of novel formulations, such as liposomal bupivacaine, can open premium markets, provided safety standards are met.

3. What are the main competitive threats for both drugs?

• For bupivacaine: low-cost generics, toxicity concerns, and substitutes like lidocaine.
• For meloxicam: intense competition from other NSAIDs, safety profile concerns, and the potential shift toward non-NSAID analgesics.

4. Which emerging markets present the greatest investment potential?

• Asia-Pacific countries show rapid growth due to rising surgical volumes (bupivacaine) and increasing chronic pain management (meloxicam).
• Market access and regulatory approval timelines are critical factors.

5. What are the key differentiators for high-value investments in these drugs?

• For bupivacaine: innovative delivery systems, safety improvements, and expanding indications.
• For meloxicam: formulation enhancements, reduction of side effects, and targeted therapies.

---

Key Takeaways

• Market Stability & Growth: Both drugs show steady growth trajectories; liposomal bupivacaine and novel meloxicam formulations offer higher growth potential with higher risk profiles.
• Regulatory & Safety Environment: Ongoing safety assessments influence market dynamics, especially for branded and innovative formulations.
• Competitive Landscape: Generics dominate, but innovation in delivery and formulation creates premium niches.
• Emerging Markets: Rapidly expanding but require navigating regulatory variability.
• Investment Focus: Prioritize formulation innovations and expanding indications, aligning with safety standards and market needs.

---

References

1. MarketsandMarkets. (2023). Global Market for Local Anesthetics.
2. Grand View Research. (2022). NSAIDs Market Size and Forecast.
3. U.S. Food and Drug Administration. (2023). Bupivacaine safety surveillance updates.
4. EMA Publications. (2022). Meloxicam clinical safety and efficacy reports.
5. GlobalData. (2022). Pain Management Market Reports.